- Home
- PAMT vs ALLO Comparison
PAMT vs ALLO Comparison
Compare PAMT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAMT
- ALLO
- Stock Information
- Founded
- PAMT 1980
- ALLO 2017
- Country
- PAMT United States
- ALLO United States
- Employees
- PAMT N/A
- ALLO N/A
- Industry
- PAMT Trucking Freight/Courier Services
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAMT Industrials
- ALLO Health Care
- Exchange
- PAMT Nasdaq
- ALLO Nasdaq
- Market Cap
- PAMT 293.5M
- ALLO 338.9M
- IPO Year
- PAMT 1985
- ALLO 2018
- Fundamental
- Price
- PAMT $14.18
- ALLO $1.45
- Analyst Decision
- PAMT Hold
- ALLO Strong Buy
- Analyst Count
- PAMT 1
- ALLO 10
- Target Price
- PAMT $16.50
- ALLO $9.66
- AVG Volume (30 Days)
- PAMT 41.1K
- ALLO 3.1M
- Earning Date
- PAMT 04-29-2025
- ALLO 05-12-2025
- Dividend Yield
- PAMT N/A
- ALLO N/A
- EPS Growth
- PAMT N/A
- ALLO N/A
- EPS
- PAMT N/A
- ALLO N/A
- Revenue
- PAMT $714,646,000.00
- ALLO $22,000.00
- Revenue This Year
- PAMT $0.61
- ALLO N/A
- Revenue Next Year
- PAMT $10.29
- ALLO $9.07
- P/E Ratio
- PAMT N/A
- ALLO N/A
- Revenue Growth
- PAMT N/A
- ALLO N/A
- 52 Week Low
- PAMT $11.01
- ALLO $1.23
- 52 Week High
- PAMT $23.70
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- PAMT N/A
- ALLO 43.61
- Support Level
- PAMT N/A
- ALLO $1.33
- Resistance Level
- PAMT N/A
- ALLO $1.53
- Average True Range (ATR)
- PAMT 0.00
- ALLO 0.14
- MACD
- PAMT 0.00
- ALLO 0.02
- Stochastic Oscillator
- PAMT 0.00
- ALLO 64.71
About PAMT PAMT CORP Common Stock
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.